Medications That Affect Bone Health: Risks & Mitigation Strategies
Medications That Affect Bone Health: Risks & Mitigation Strategies
Many commonly prescribed drugs negatively impact bone density or quality. Awareness enables proactive protection. Here's a breakdown by drug class.
| Drug Class | Mechanism of Bone Harm | Clinical Context | Mitigation |
|---|---|---|---|
| Glucocorticoids (prednisone ≥5 mg/day × 3+ mo) | ↓ Osteoblastogenesis, ↑ osteoclast survival, ↓ Ca absorption, ↑ renal Ca loss, ↓ sex hormones | Highest risk: first 3–6 mo. Dose/duration dependent. | Lowest effective dose; Ca/D supplementation; bisphosphonate if high risk; weight-bearing exercise; fall prevention. |
| Proton Pump Inhibitors (long-term) | ↓ Gastric acid → ↓ Ca carbonate absorption; possible ↓ osteoclast function via vacuolar ATPase | Observational: ↑ fracture risk (hip, spine, wrist) with >1 yr use. | Use lowest dose/duration; switch to H2RA if possible; calcium citrate (acid-independent); monitor BMD. |
| Anticonvulsants (phenytoin, carbamazepine, phenobarbital, valproate) | Induce CYP450 → ↑ vitamin D catabolism → ↓ Ca absorption; direct osteoblast toxicity (valproate) | Chronic epilepsy populations. | Vitamin D supplementation (target >30 ng/mL); consider newer AEDs (levetiracetam, lamotrigine); BMD monitoring. |
| Aromatase Inhibitors (letrozole, anastrozole, exemestane) | Profound estrogen suppression → ↑ bone turnover, rapid loss | Breast cancer adjuvant therapy (5–10 yrs). | Baseline DEXA; bisphosphonate/denosumab if T-score < -1.5 or risk factors; exercise; Ca/D. |
| Androgen Deprivation Therapy (GnRH agonists/antagonists) | Testosterone → estradiol conversion blocked → bone loss in men | Prostate cancer. 2–4% BMD loss/yr initially. | Baseline DEXA; denosumab 60 mg q6mo or zoledronic acid q1yr; Ca/D; resistance training. |
| Antidepressants (SSRIs) | Serotonin receptors on osteoblasts/osteoclasts; ↑ fall risk | Meta-analyses: modest ↑ fracture risk. | Fall risk assessment; consider non-SSRI if high fracture risk; BMD monitoring. |
| Loop Diuretics (furosemide) | ↑ Urinary Ca excretion | HF, CKD, edema. | Thiazide alternative if possible (thiazides ↓ Ca excretion); Ca supplementation; monitor. |
| Methotrexate (high-dose) | ↓ Osteoblast proliferation; folate antagonism | Oncology doses > rheumatology doses. | Leucovorin rescue; Ca/D; BMD monitoring in long-term high-dose. |
| Depo-Provera (DMPA) | Hypoestrogenism → BMD loss (reversible after discontinuation) | Contraception; adolescents/young women concern for peak bone mass. | Limit to 2 yrs if possible; Ca/D; weight-bearing exercise; consider alternatives. |
Action Plan: Review med list with pharmacist/PCP annually. If on bone-harming therapy ≥3 months: baseline DEXA, Ca/D optimization, fall assessment, consider bone-protective agent per guidelines (AACE, NOF, ASCO).
Bones, Joints & Muscles - Related Articles
- Sartorius Muscle Injury: Causes, Symptoms & Treatment
- Ganglion Cysts: Hand & Wrist Pain – Symptoms, Causes & Diagnosis
- Shoulder Abduction Muscles: Prime Movers, Synergists & Clinical Testing
- Hip Pain Relief: Understanding Causes & Simple Solutions
- Lower Groin Injury Treatment: Rest, Recovery & Rehabilitation
- Ultrasonic Shockwave Therapy for Plantar Fasciitis: Benefits & Effectiveness
- Numb Fingertips: Causes, Relief & When to See a Doctor
